Aventis To Pay $96M To End Medicaid Rebate Probe

Law360, New York (May 28, 2009, 12:00 AM EDT) -- Aventis Pharmaceutical Inc. has agreed to pay $95.5 million to settle allegations that the drugmaker violated federal law by misreporting nasal spray prices in order to reduce its Medicaid rebate obligations.

The Sanofi-Aventis U.S. LLC subsidiary will give the U.S. government roughly $49 million; turn over $40 million to participating state Medicaid programs; and pay more than $6 million to public health service programs that overpaid for Aventis' Azmacort, Nasacort and Nasacort AQ, the U.S. Department of Justice announced Thursday.

The deal brings an end to...
To view the full article, register now.